153 Series A biotech investors
We list 153 Series A biotech investors as of November 2026: 60 have an SEC filing on file and 93 were checked on the firm's own website or an official register, and the list was last checked on 7 Nov 2026. The states with the most are California (21), New York (8) and Massachusetts (5).
Top 5 Series A biotech investors, ranked by recent fund activity
Among firms with a published profile and a dated fund or deal in the last 24 months. The rule: Activity score out of 100: recency of the latest fund filing or dated deal (35: full marks within 3 months, then stepping down at 6, 12 and 24 months), share of the observed portfolio in this sector (25; half of that when the sector is stated only), stage focus (15: all of it when Series A is the only stage the firm states, split evenly when it states more), size of the fund on file on a log scale (15) and completeness of the public record (10). Stage focus is our research, not an SEC figure. It is a measure of activity and fit, not of quality or returns. The same rule orders the whole list; it is repeated in the method box.
Cambridge Innovation Capital
Type: VC firm · HQ: Cambridge, United Kingdom · Stages: Seed, Series A, Growth · Focus: Biotech, Healthtech, AI, Fintech · Latest activity: New fund, Oct 2026 · Fund size or assets: £600M (own site)
Latest fund filing dated Oct 2026; £600M on file (own site); 53% of its observed portfolio is biotech and life sciences; backs seed, Series A, growth-stage; 8 named decision-makers on file.
Felicis
Type: VC firm · HQ: Menlo Park, CA · Stages: Seed, Series A · Focus: Biotech, AI, Developer Tools, Healthtech · Latest activity: New deal, Oct 2026 · Fund size on file: $900M (SEC Form D, 2025)
Dated new deal in Oct 2026; $900M fund on file (SEC Form D, 2025); states biotech and life sciences as a focus; backs seed, Series A; 8 named decision-makers on file.
Angelor
Type: VC firm · HQ: Lyon, France · Stages: Seed, Series A · Focus: Biotech, Healthtech, Medtech, Food and Beverage · Latest activity: New deal, Sep 2026 · Fund size or assets: €100M (own site)
Dated new deal in Sep 2026; €100M on file (own site); states biotech and life sciences as a focus; backs seed, Series A; 1 named decision-maker on file.
SHD Partners
Type: VC firm · HQ: Dallas, TX · Stages: Seed, Series A · Focus: Biotech, Healthtech, Medtech · Latest activity: Portfolio news, Nov 2026 · Private fund assets: $61M (SEC Form ADV)
Portfolio news dated Nov 2026; $61M on file (SEC Form ADV); 29% of its observed portfolio is biotech and life sciences; backs seed, Series A; 6 named decision-makers on file.
HBM Partners
Type: Fund manager · HQ: Zug, Switzerland · Stages: Series A, Series B, Growth, Late stage · Focus: Biotech, Healthtech, Medtech · Latest activity: Portfolio news, Oct 2026 · Fund size or assets: $2.8B (own site)
Portfolio news dated Oct 2026; $2.8B on file (own site); states biotech and life sciences as a focus; backs Series A, Series B, growth-stage; 1 named decision-maker on file.
First 25 of 153 Series A biotech investors
| Investor | Type | HQ | Stagesour research | Focusour research | Latest fund or deal | Fund sizeas filed or stated | Checked | Contacts |
|---|---|---|---|---|---|---|---|---|
| Cambridge Innovation Capital | VC firm | Cambridge, United Kingdom | Seed, Series A, Growth | Biotech, Healthtech, AI, Fintech | New fund, Oct 2026 | £600M (own site) | 4 Nov 2026 | 8 names, firm email · Unlock |
| Felicis | VC firm | Menlo Park, CA | Seed, Series A | Biotech, AI, Developer Tools, Healthtech | New deal, Oct 2026 | $900M (SEC Form D, 2025) | 5 Nov 2026 | 8 names · Unlock |
| Angelor | VC firm | Lyon, France | Seed, Series A | Biotech, Healthtech, Medtech, Food and Beverage | New deal, Sep 2026 | €100M (own site) | 7 Nov 2026 | 1 name · Unlock |
| SHD Partners | VC firm | Dallas, TX | Seed, Series A | Biotech, Healthtech, Medtech | Portfolio news, Nov 2026 | $61M (SEC Form ADV) | 5 Nov 2026 | 6 names, firm email · Unlock |
| HBM Partners | Fund manager | Zug, Switzerland | Series A, Series B, Growth, Late stage | Biotech, Healthtech, Medtech | Portfolio news, Oct 2026 | $2.8B (own site) | 7 Nov 2026 | 1 name, firm email · Unlock |
| Epidarex Capital | VC firm | Edinburgh, United Kingdom | Seed, Series A | Biotech, Healthtech, Medtech | Portfolio news, Jul 2026 | $17M (SEC Form ADV) | 4 Nov 2026 | 8 names, firm email · Unlock |
| Andera Partners | Fund manager | Paris, France | Seed, Series A, Series B, Growth | Biotech, Medtech, Healthtech, Generalist | Portfolio news, Sep 2026 | €6.0B (own site) | 7 Nov 2026 | No contact on file |
| Biovance Capital | VC firm | Lisbon, Portugal | Seed, Series A | Biotech, Healthtech | New deal, Sep 2026 | €60M (own site) | 7 Nov 2026 | 4 names · Unlock |
| Claris Ventures | VC firm | Turin, Italy | Pre-seed, Seed, Series A | Biotech, Healthtech | New fund, Oct 2026 | €190M (own site) | 7 Nov 2026 | 4 names, firm email · Unlock |
| BGF | VC firm | United Kingdom | Seed, Series A, Series B, Growth | Biotech, Healthtech, Edtech, Developer Tools | Portfolio news, Oct 2026 | £3.0B (own site) | 4 Nov 2026 | 8 names · Unlock |
| Outlier Ventures | VC firm | United Kingdom | Pre-seed, Seed, Series A, Growth | Biotech, AI, Robotics, Fintech | New deal, Oct 2026 | $500M (own site) | 4 Nov 2026 | LinkedIn page · Unlock |
| Hadean Ventures | VC firm | Norway | Seed, Series A, Series B | Biotech, Healthtech, Medtech | New deal, Sep 2026 | €230M (own site) | 7 Nov 2026 | 3 names, firm email · Unlock |
| Madrona | VC firm | Seattle, WA | Pre-seed, Seed, Series A, Series B, Growth | Biotech, AI, Consumer, Deep Tech | New deal, Oct 2026 | $490M (SEC Form D, 2025) | 5 Nov 2026 | 8 names · Unlock |
| 819 Capital Partners | VC firm | Deventer, Netherlands | Seed, Series A, Growth | Biotech, Healthtech, Medtech, Generalist | Portfolio news, Sep 2026 | €100M (own site) | 7 Nov 2026 | 1 name, firm email · Unlock |
| Bison Ventures | VC firm | San Francisco, CA | Pre-seed, Seed, Series A, Series B | Biotech, AI, Healthtech, Energy | New fund, Oct 2026 | $160M (SEC Form D, 2025) | 4 Nov 2026 | 2 names, firm email · Unlock |
| Sofinnova Partners | VC firm | France (London office) | Seed, Series A, Series B, Growth | Biotech, Healthtech, Fintech, Agritech | New fund, Nov 2025 | €4.0B (own site) | 5 Nov 2026 | 8 names · Unlock |
| Magnetic Ventures | VC firm | Miami Beach, FL | Seed, Series A | Biotech, AI, Healthtech, Edtech | New fund, Mar 2026 | $100M (SEC Form D, 2022) | 4 Nov 2026 | 3 names, firm email · Unlock |
| DeepWork Capital | VC firm | Orlando, FL | Seed, Series A | Biotech, Healthtech, Fintech, AI | New deal, Jun 2026 | $100M (SEC Form D, 2023) | 5 Nov 2026 | 8 names · Unlock |
| Kapor Capital | VC firm | Oakland, CA | Pre-seed, Seed, Series A | Biotech, Edtech, Fintech, Healthtech | New deal, Jun 2026 | $125M (SEC Form D, 2021) | 5 Nov 2026 | 5 names · Unlock |
| Cornucopian Capital | VC firm | Montclair, NJ | Pre-seed, Seed, Series A, Series B | Biotech, Healthtech, AI, Medtech | New fund, Aug 2026 | $12M (SEC Form D, 2024) | 4 Nov 2026 | 1 name · Unlock |
| Archangels | Angel network | Edinburgh, United Kingdom | Pre-seed, Seed, Series A, Growth | Biotech, Media, Deep Tech, Healthtech | Portfolio news, Nov 2026 | £10M (own site) | 4 Nov 2026 | 8 names, firm email · Unlock |
| Union Square Ventures | VC firm | New York, NY | Seed, Series A | Biotech, AI, Generalist, Robotics | New deal, Oct 2026 | $3M (SEC Form D, 2026) | 4 Nov 2026 | 8 names · Unlock |
| Draper Associates | VC firm | San Mateo, CA | Pre-seed, Seed, Series A | Biotech, AI, Fintech, Healthtech | New fund, Oct 2026 | $301M (SEC Form D, 2025) | 4 Nov 2026 | 8 names · Unlock |
| Wellington Partners | VC firm | Munich, Germany | Series A, Series B, Growth | Biotech, Healthtech, Medtech | Portfolio news, May 2026 | €210M (own site) | 4 Nov 2026 | 8 names · Unlock |
| MGP Venture Fund III | VC firm | Nashville, TN | Series A | Biotech, Healthtech, Agritech, Energy | Portfolio news, Jul 2025 | $150M (SEC Form D, 2021) | 5 Nov 2026 | 7 names, firm email · Unlock |
You are seeing 25 of 153. The full list adds 128 more investors and 785 named decision-makers.
One-time payment. No subscription. No account.
Or get the free sample.
How these 153 break down
By region
| Region | On this list | Share |
|---|---|---|
| United States | 59 | 39% |
| United Kingdom | 38 | 25% |
| Europe | 55 | 36% |
By US state
| US state | On this list | Share |
|---|---|---|
| California | 21 | 14% |
| New York | 8 | 5% |
| Massachusetts | 5 | 3% |
| Texas | 4 | 3% |
| Florida | 3 | 2% |
| New Jersey | 2 | 1% |
| Tennessee | 2 | 1% |
| Michigan | 2 | 1% |
| Illinois | 2 | 1% |
| Oregon | 2 | 1% |
By European country
| European country | On this list | Share |
|---|---|---|
| France | 10 | 7% |
| Germany | 9 | 6% |
| Netherlands | 8 | 5% |
| Spain | 5 | 3% |
| Sweden | 5 | 3% |
| Belgium | 3 | 2% |
| Austria | 3 | 2% |
| Portugal | 2 | 1% |
By type
| Type | On this list | Share |
|---|---|---|
| VC firm | 120 | 78% |
| Fund manager | 11 | 7% |
| Government or university fund | 8 | 5% |
| Angel network | 4 | 3% |
| Accelerator | 2 | 1% |
| Single family office | 2 | 1% |
Method and limits
- Source
- 60 of the 153 rows carry an SEC filing (Form D or Form ADV). All 153 have a website we checked. Filing date and fund size are SEC data where a filing exists. Stage, sector and check size are our research.
- Inclusion rule
- Organizations that back startups. Individuals, buyout funds and firms we found to be inactive are left out. Sector: the firm states biotech and life sciences as a focus on its own site, or we observed it in the firm's portfolio. Stage: the firm states that it invests at Series A.
- Order
- Firms with a published profile come first. Activity score out of 100: recency of the latest fund filing or dated deal (35: full marks within 3 months, then stepping down at 6, 12 and 24 months), share of the observed portfolio in this sector (25; half of that when the sector is stated only), stage focus (15: all of it when Series A is the only stage the firm states, split evenly when it states more), size of the fund on file on a log scale (15) and completeness of the public record (10). Stage focus is our research, not an SEC figure. It is a measure of activity and fit, not of quality or returns.
- Last refreshed
- November 2026. Rows on this list were checked between 4 Nov 2026 and 7 Nov 2026.
- Fill rates
- Of 153 rows: stage 153, sector 153, fund size 91, website 153. In the paid file: named decision-makers on 145 rows, firm email on 86, LinkedIn page on 110, check size on 46.
- Corrections
- Email hello@theinvestordatabase.com or use the update form. We act within 5 working days.
Questions
How many Series A biotech investors are there?
We list 153 as of November 2026. 83 of the 153 have a fund filing or a dated deal in the last 12 months.
Which Series A biotech investors raised a new fund in the last 12 months?
23 of the 153 have a fund filing dated in the last 12 months. The most recent on this list are Draper Associates (Oct 2026), Bison Ventures (Oct 2026) and Overlap Holdings (Oct 2026).
What is the typical fund size of Series A biotech investors?
The median fund size on file for this list is $90M, across the 39 firms with a size on an SEC Form D. The fund on file is each firm's main fund, which is not always its newest. The other 114 do not disclose a size there.
How do I contact Series A biotech investors?
The paid file holds 785 named decision-makers across 145 of these 153 and a firm email for 86. We publish the address a firm lists itself, never a personal email. Each free row links to a profile with the firm's website.
Where does the data on Series A biotech investors come from?
60 of the 153 rows have an SEC filing on file (Form D or Form ADV) and 93 were checked on the firm's own website or an official register. Filing date and fund size come from the filing. Stage, sector and check size are our research. Rows on this list were last checked on 7 Nov 2026 at the latest. The whole file is re-verified twice a year.
Broader lists
Narrower lists
Related lists
Series A AI investors (500)Series A SaaS investors (475)Series A healthtech investors (401)Seed biotech investors (300)Series A fintech investors (294)Series A deep tech investors (293)Series A climate tech investors (263)Series A B2B investors (157)Series A consumer investors (154)Pre-seed biotech investors (148)Series A energy investors (139)Series A medtech investors (125)Series A cybersecurity investors (118)Series A industrial tech investors (113)Growth-stage biotech investors (109)Series A hardware investors (82)Series B biotech investors (73)Series A mobility investors (70)
Not sure this is the right list? Describe your raise in the investor matching tool and get a shortlist. The link opens it set to biotech and life sciences and Series A. Guide: how many investors to pitch. Markdown version of this page.
Check the quality first
A free sample of 100 investors, every column, with sources and dates.